Neurocrine Biosciences Inc.’s stock (NASDAQ:NBIX) has been rated as Buy by Citigroup. This latest rating was contained in a recent research note published by the firm on March 06, 2020 and has set a $124 price target for the stock. Some experts on Wall Street have also posted a report on Neurocrine Biosciences Inc. (NBIX) stock.
Barclays rated the stock as a Equal Weight in a research noted published on February 27, 2020. William Blair rated the stock as a Outperform in a research note published on February 24, 2020.
As it stands, a total of 23 analysts are covering NBIX stock, with 16 of them rating it as a Buy while 1 of them rating it as Overweight. 6 analysts meanwhile advised investors to Hold, 0 rated it as Underweight while the 0 rated it as a Sell. A look at the overall ratings means that Neurocrine Biosciences Inc. (NBIX) stock has an average rating of Overweight.
Neurocrine Biosciences Inc. (NBIX) which is currently valued at 11.05 billion, with the company publishing its last earnings report on 05/06/2020, for the recent quarter of 2019. In that quarter, the company recorded a revenue of 223.87 million, which was lower than the forecast of 245.0 million made by some analysts. For that same quarter, Neurocrine Biosciences Inc. (NBIX) posted -$1.12 earnings per share (EPS) which was below the analyst consensus estimate of -$0.92 by -$0.2, which represents a decrease by -21.70%.
The stock market has a tendency to become sophisticated sometimes, even for seasoned investors and traders. Even when a trader got what he/she had expected, the market sometimes decides to move in the opposite direction. This volatility sometimes leads to some traders doubting and second-guessing their moves. This is why getting to know historical price performance, as well as both long-term and short-term trends, is very important. Over the past one week, NBIX price has surged by 8.89%. A look at its price performance over the past three months sees the stock go up by 20.37%, while it has gain 8.30% over the past six months and 58.13% since the start of the year.
Let us now look at some of its likely support and resistance level. Recent research on Neurocrine Biosciences Inc. (NBIX) has seen its stock trading -2.45% below its three-month high price. A look at the other side also sees stock trading +72.11% above its three-month low. A wider look sees NBIX trading -2.45% below its 52-week high and 72.11% above from its 52-week low price.
Shareholders of the company sometimes like to find out how their investments are growing. Neurocrine Biosciences Inc. (NBIX) has so far given an ROE of 29.50%. When the ROE is low, it means that the company isn’t generating enough profits. The Return on Assets (ROA) ratio meanwhile is an indication of how profitable a company is relative to the total asset it owns. Neurocrine Biosciences Inc. (NBIX)’s ROA at the moment stands at 14.40%. Any company that is managing its assets better will have a higher return while one that manages assets poorly would result in low returns.
Neurocrine Biosciences Inc. (NBIX) has a return on investment (ROI) of 6.00%. The higher the ROI percentage, the higher the profit exceeds the costs, thus analysts consider such investments as an overall gain. A negative ROI, however, means that the cost is higher than the profits, a scenario analysts consider as a net loss.
Let us now take a look at Neurocrine Biosciences Inc. (NBIX)’s trading volatility. Its 7-day volatility is around 4.86%, while it has a monthly volatility of 4.36%. NBIX has an ATR (Average True Range) of 5.07 and a beta factor of 1.21. The volatility of a stock is an indication of the stock’s drop or gain in case the wider market drops or surges. A beta score higher than 1 means that a stock is highly volatile while below 1 means that the volatility of a stock is low.
The price of NBIX lifted by $4.23 during the normal trading session on Wednesday to trade at $124.16. The Neurocrine Biosciences Inc. (NBIX) stock has a trading volume of 0.93 million shares, which is high, compared to its average daily volume of 881.19K shares.